Prevention of bleomycin-induced lung fibrosis via inhibition of the MRTF/SRF transcription pathway.

Pawelec, Kendell M; Varnum, Megan; Harkema, Jack R; Auerbach, Bruce; Larsen, Scott D; Neubig, Richard R

Pawelec, Kendell M; Varnum, Megan; Harkema, Jack R; Auerbach, Bruce; Larsen, Scott D; Neubig, Richard R.

Afiliación

Pawelec KM; FibrosIX, East Lansing, Michigan, USA.
Varnum M; FibrosIX, East Lansing, Michigan, USA.
Harkema JR; BBC Entrepreneurial Training and Consulting, Chelsea, Michigan, USA.
Auerbach B; Department of Pathology and Diagnostic Investigation, Michigan State University, East Lansing, Michigan, USA.
Larsen SD; Department of Pharmacology & Toxicology, Michigan State University, East Lansing, Michigan, USA.
Neubig RR; Office of Technology Transfer, University of Michigan, Ann Arbor, Michigan, USA.

Pharmacol Res Perspect ; 10(6): e01028, 2022 12.

Article en En | MEDLINE | ID: mdl-36426895

Asunto(s)

Bleomicina; Fibrosis Pulmonar; Humanos; Animales; Ratones; Bleomicina/toxicidad; Fibrosis Pulmonar/inducido químicamente; Fibrosis Pulmonar/tratamiento farmacológico; Fibrosis Pulmonar/prevención & control; Inflamación; Fibroblastos; Prednisolona

Palabras clave

MRTF/SRF inhibitor; drug-induced lung fibrosis; nintedanib; prevention model

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Fibrosis Pulmonar / Bleomicina Tipo de estudio: Prognostic_studies Límite: Animals / Humans Idioma: En Revista: Pharmacol Res Perspect Año: 2022 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Estados Unidos

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google